Objective: Detection of factors that affect the success of single-dose methotrexate treatment in ectopic pregnancy.
Materials And Methods: We investigated 99 patients who had been treated with single-dose methotrexate for ectopic pregnancy in our clinic between January 2009 and June 2014. Demographic, clinical, and laboratory results of possible factors that affect treatment success were retrospectively analyzed. Successfully and unsuccessfully treated patients were compared based on their pre-treatment results.
Results: The success rate of single-dose methotrexate treatment was found to be 70.7%. No significant difference was found between succesfully and unsuccessfully treated patients before treatment in terms of factors such as gestational weeks, mass size, presence of yolk sac, and presence of free fluid (p=0.224, p=0.201, p=0.200, p=0.200). Serum β-hCG values in patients whose treatment was unsuccessful was found to be higher compared with the successfully treated group (mean β-hCG value of unsuccessful group: 4412±3501 mIU/mL; mean β-hCG value of successful group: 1079±942 mIU/mL; p<0.001).
Conclusion: Single-dose methotrexate treatment is an effective and reliable method in the treatment of ectopic pregnancy. Elevation of serum β-hCG value stands as the main prognostic factor that affects the success of single-dose methotrexate treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588474 | PMC |
| http://dx.doi.org/10.4274/tjod.10576 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictors of treatment failure of tubal pregnancy with single-dose methotrexate regimen - a systematic review and meta-analysis.
J Obstet Gynaecol
December 2025
Department of Obstetrics and Gynecology, the Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
Background: Ectopic pregnancies represent a potentially life-threatening medical emergency, with 95% being tubal. This meta-analysis aimed to identify early predictors for single-dose methotrexate (MTX) treatment failure in tubal pregnancies.
Methods: A literature search was conducted across several databases from their inception to December 2023, with references in the selected studies manually reviewed.
Evaluating single-dose methotrexate alone versus methotrexate with letrozole for treating ectopic pregnancy: a comparative study.
Arch Gynecol Obstet
December 2024
Faculty of Medicine, Department of Gynecology and Obstetrics, Van Yuzuncu Yil University, Van, Turkey.
Purpose: Ectopic pregnancy (EP) constitutes 1-2% of all pregnancies. Methotrexate (MTX) is commonly used in treating EP, but it has some limitations and potential side effects. Clinical studies have shown that letrozole, an aromatase inhibitor, may potentially be used in conjunction with MTX therapy.
View Article and Find Full Text PDFHumanized anti-CD25 monoclonal antibody replaces methotrexate as acute graft-versus-host disease prophylaxis in haploidentical allogeneic haematopoietic stem cell transplantation.
Br J Haematol
December 2024
Institute of Hematology, Union Hospital, Tongji Medicine College, Huazhong University of Science and Technology, Wuhan, China.
Acute graft-versus-host disease (aGVHD) significantly affects quality of life and outcomes in patients post-haploidentical haematopoietic stem cell transplantation (haplo-HSCT). Methotrexate (MTX) is commonly used to prevent aGVHD but can lead to complications like delayed haematological recovery and oral mucositis (OM). This study investigates the efficacy of anti-CD25 monoclonal antibody (mAb) as a potential MTX alternative.
View Article and Find Full Text PDFThe role of inflammatory markers and βhCG levels in predicting the success of single-dose methotrexate treatment in tubal ectopic pregnancy.
Int J Gynaecol Obstet
December 2024
Department of Obstetrics and Gynecology, Konya City Hospital, Konya, Turkey.
Objective: To evaluate the predictive ability of serum beta human chorionic gonadotropin (βhCG) levels and inflammatory markers derived from hemogram parameters in the success of methotrexate (MTX) treatment for tubal ectopic pregnancy.
Methods: This retrospective study involved the examination of patients diagnosed with tubal ectopic pregnancy and treated with a single dose of MTX at our clinic between 2018 and 2023. The monocyte-to-lymphocyte ratio (MLR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were calculated from blood samples taken at the time of presentation.
Potential Effect of Etoricoxib in Reducing Inflammation in Methotrexate-Induced Pulmonary Injury in Rats: Role of Oxidative Stress and the TLR4/p38-MAPK/NF-κB Signaling Pathway.
Inflammation
November 2024
Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia, 61519, Egypt.
Article Synopsis
- Chemotherapy drugs like Methotrexate (MTX) can cause serious lung damage, with MTX being particularly toxic and having various side effects, including lung injury.
- The study investigated the effect of etoricoxib (ETO) in reducing MTX-induced lung damage in male rats, with different treatment groups comparing controls, MTX alone, ETO alone, and ETO after MTX.
- Results showed that ETO improved lung tissue structure and restored balance in oxidant/antioxidant levels, while also normalizing inflammatory markers and pathways linked to lung inflammation, suggesting ETO may protect against MTX toxicity.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!